Objective: To study the effect of smoking status at diagnosis on recurrence in intermediate risk (IR) non-muscle invasive bladder carcinoma (NMIBC) treated by TUR and early intravesical chemotherapy. Methods: Tumor characteristics and smoking status were recorded in 395 patients entered in a randomized multicenter trial comparing two different schedules of early intravesical chemotherapy. All patients received intravesical epirubicin (80mg/50 ml) within 6 hours after TUR followed by 5 more weekly instillations with (Arm B) or without (Arm A) monthly instillations for one year. Smoking habit was investigated at diagnosis through a structured questionnaire. Multivariate statistical analysis was performed to study the recurrence-free survival (RFS) and the recurrence-free rate (RFR) in relation to smoking status. Results: Nine-seven (24,6%) patients never smoked and 298 (75,4%) were smokers. At a median follow-up of 48 months, 117 patients (29.6%) recurred, 63 in arm A and 54 in arm B (p=0.43). Ten patients (2.5%) progressed. The 3-year RFS, RFR and median time to first recurrence of smokers and patients who never smoked were 64.0% and 71.3% (p.=0.08), 69.1% and 74.2% (p.=0.16) and 13.6 and 14.2 months (p.=0.27) respectively. The multivariate analysis identified the previous history (p.=0.01) and the smoking status (p.=0.04) as the main prognostic factors for recurrence in this category of patients. No difference in recurrence risk at 3 years was detected between current and former smokers Conclusions: In intermediate risk NMIBC treated by early intravesical chemotherapy the smoking status influences significantly the 3-year RFS. No difference was detected between current and former smokers.

Serretta, V., Altieri, V., Morgia, G., Di Lallo, A., Carrieri, G., Allegro, R. (2013). Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma. UROLOGY, 81(81), 277-282 [10.1016/j.urology.2012.09.040].

Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma

SERRETTA, Vincenzo;ALLEGRO, Rosalinda
2013-01-01

Abstract

Objective: To study the effect of smoking status at diagnosis on recurrence in intermediate risk (IR) non-muscle invasive bladder carcinoma (NMIBC) treated by TUR and early intravesical chemotherapy. Methods: Tumor characteristics and smoking status were recorded in 395 patients entered in a randomized multicenter trial comparing two different schedules of early intravesical chemotherapy. All patients received intravesical epirubicin (80mg/50 ml) within 6 hours after TUR followed by 5 more weekly instillations with (Arm B) or without (Arm A) monthly instillations for one year. Smoking habit was investigated at diagnosis through a structured questionnaire. Multivariate statistical analysis was performed to study the recurrence-free survival (RFS) and the recurrence-free rate (RFR) in relation to smoking status. Results: Nine-seven (24,6%) patients never smoked and 298 (75,4%) were smokers. At a median follow-up of 48 months, 117 patients (29.6%) recurred, 63 in arm A and 54 in arm B (p=0.43). Ten patients (2.5%) progressed. The 3-year RFS, RFR and median time to first recurrence of smokers and patients who never smoked were 64.0% and 71.3% (p.=0.08), 69.1% and 74.2% (p.=0.16) and 13.6 and 14.2 months (p.=0.27) respectively. The multivariate analysis identified the previous history (p.=0.01) and the smoking status (p.=0.04) as the main prognostic factors for recurrence in this category of patients. No difference in recurrence risk at 3 years was detected between current and former smokers Conclusions: In intermediate risk NMIBC treated by early intravesical chemotherapy the smoking status influences significantly the 3-year RFS. No difference was detected between current and former smokers.
Settore MED/24 - Urologia
http://dx.doi.org/10.1016/j.urology.2012.09.040
Serretta, V., Altieri, V., Morgia, G., Di Lallo, A., Carrieri, G., Allegro, R. (2013). Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma. UROLOGY, 81(81), 277-282 [10.1016/j.urology.2012.09.040].
File in questo prodotto:
File Dimensione Formato  
Urology_2013.pdf

Solo gestori archvio

Descrizione: articolo
Dimensione 133.33 kB
Formato Adobe PDF
133.33 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/70143
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 29
social impact